Edition:
United States

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.73USD
12:05pm EDT
Change (% chg)

$0.26 (+3.48%)
Prev Close
$7.47
Open
$7.50
Day's High
$7.76
Day's Low
$7.42
Volume
45,344
Avg. Vol
126,624
52-wk High
$14.00
52-wk Low
$4.10

Select another date:

Wed, Aug 8 2018

REFILE-UPDATE 3-Insys to pay $150 mln to settle U.S. opioid kickback probe

Aug 8 Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Insys to pay $150 million to settle U.S. opioid kickback probe

Insys Therapeutics said on Wednesday it had reached a deal to pay at least $150 million to resolve a U.S. Justice Department investigation into claims that the drugmaker paid doctors kickbacks to prescribe a powerful opioid medication.

Insys to pay $150 mln to settle DoJ probe

Aug 8 Insys Therapeutics said on Wednesday it had reached an agreement in principle with the U.S. Department of Justice to settle a civil and criminal investigation into inappropriate sales and commercial practices by some former company employees.

FDA declines to approve Insys Therapeutic's opioid painkiller

Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

UPDATE 1-FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns.

FDA declines to approve Insys Therapeutic's opioid painkiller

July 27 Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration had declined to approve its opioid painkiller, citing potential safety concerns.

U.S. to narrow opioid bribe case against Insys founder, others

BOSTON U.S. prosecutors on Tuesday said they will narrow a case against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe a potent opioid after a federal judge questioned the scope of the indictment charging them.

UPDATE 2-U.S. to narrow opioid bribe case against Insys founder, others

BOSTON, July 24 U.S. prosecutors on Tuesday said they will narrow a case against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe a potent opioid after a federal judge questioned the scope of the indictment charging them.

U.S. to narrow opioid bribe case against Insys founder, others

BOSTON, July 24 U.S. prosecutors on Tuesday said they will narrow a case against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe an opioid after federal judge questioned the scope of the indictment charging them.

U.S. judge questions scope of indictment against Insys founder

BOSTON A federal judge on Tuesday expressed concern about the scope of an indictment against several former Insys Therapeutics Inc executives accused of bribing doctors to prescribe an opioid and suggested U.S. prosecutors streamline the case to avoid its dismissal.

Select another date: